NCT02173704View on ClinicalTrials.gov

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

September 11, 2014

Primary Completion Date

December 25, 2015

Study Completion Date

June 17, 2016

Conditions
Meningococcal DiseaseInfections, Meningococcal
Interventions
BIOLOGICAL

Bexsero®

Four doses administered in the anterolateral area of the right or left thigh.

BIOLOGICAL

Routine vaccines

Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.

Trial Locations (2)

10041

GSK Investigational Site, Taipei

10449

GSK Investigational Site, Taipei

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT02173704 - Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. | Biotech Hunter | Biotech Hunter